OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera

Current therapies for high-grade gliomas, particularly glioblastomas (GBM), do not extend patient survival beyond 16–22 months. OKN-007 (OKlahoma Nitrone 007), which is currently in phase II (multi-institutional) clinical trials for GBM patients, and has demonstrated efficacy in several rodent and h...

Descripción completa

Detalles Bibliográficos
Autores principales: Towner, Rheal A., Hocker, James, Smith, Nataliya, Saunders, Debra, Battiste, James, Hanas, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773900/
https://www.ncbi.nlm.nih.gov/pubmed/35053843
http://dx.doi.org/10.3390/brainsci12010100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773900/
https://www.ncbi.nlm.nih.gov/pubmed/35053843
http://dx.doi.org/10.3390/brainsci12010100

Ejemplares similares